trending Market Intelligence /marketintelligence/en/news-insights/trending/W5quHIdbcRapI0BhR7dZ1w2 content esgSubNav
In This List

Zimmer Biomet's meniscus repair device approved for marketing in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Zimmer Biomet's meniscus repair device approved for marketing in US

Zimmer Biomet Holdings Inc.'s meniscal repair device JuggerStitch was approved in the U.S. under the Food and Drug Administration's 510(k) regulatory pathway.

The device is meant to treat a meniscus tear in the knee via keyhole surgery. Compared to traditional surgery techniques, JuggerStitch offers a lesser invasive method of treatment.

JuggerStitch features two soft anchors connected by a knotless, self-locking suture loop for better tissue preservation and improved surgeon's control of the tissue compression at the repair site, the company said in a press release.

Zimmer Biomet designs and markets musculoskeletal healthcare products for the U.S. and international markets.